Abstract
Building closures related to the coronavirus disease (COVID-19) pandemic resulted in increased water stagnation in commercial building plumbing systems that heightened concerns related to the microbiological safety of drinking water post re-opening. The exact impact of extended periods of reduced water demand on water quality is currently unknown due to the unprecedented nature of widespread building closures. We analyzed 420 tap water samples over a period of six months, starting the month of phased reopening (i.e., June 2020), from sites at three commercial buildings that were subjected to reduced capacity due to COVID-19 social distancing policies and four occupied residential households. Direct and derived flow cytometric measures along with water chemistry characterization were used to evaluate changes in plumbing-associated microbial communities with extended periods of altered water demand. Our results indicate that prolonged building closures impacted microbial communities in commercial buildings as indicated by increases in microbial cell counts, encompassing greater proportion cells with high nucleic acids. While flushing reduced cell counts and increased disinfection residuals, the microbial community composition in commercial buildings were still distinct from those at residential households. Nonetheless, increased water demand post-reopening enhanced systematic recovery over a period of months, as microbial community fingerprints in commercial buildings converged with those in residential households. Overall, our findings suggest that sustained and gradual increases in water demand may play a more important role in the recovery of building plumbing-associated microbial communities as compared to short-term flushing, after extended periods of altered water demand that result in reduced flow volumes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by NSF CBET 2029850 and NSF CBET 1743950.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw FCS files have been deposited in FlowRepository and are publicly available under accession number FR-FCM-Z4SR.
